Csenge Advisory Group Acquires 2,566 Shares of Johnson & Johnson $JNJ

Csenge Advisory Group increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,628 shares of the company’s stock after buying an additional 2,566 shares during the quarter. Csenge Advisory Group’s holdings in Johnson & Johnson were worth $3,357,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson during the 1st quarter worth approximately $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.3%

NYSE JNJ opened at $186.89 on Wednesday. The firm has a market capitalization of $450.27 billion, a P/E ratio of 18.04, a PEG ratio of 2.19 and a beta of 0.40. The business has a fifty day simple moving average of $183.64 and a 200 day simple moving average of $168.16. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. UBS Group boosted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.